0
0
6/13/23 at 2:15pm
Organization
European Pharmaceutical Review
27 words
0
Comments
If approved, VLA1553 could become the first licensed chikungunya vaccine available to address this unmet medical need.
You are the first to view
https://www.europeanpharmaceuticalreview.com/news/183546/chikungunya-vaccine-demonstrates-99-percent-immune-response/
Create an account
or login to join the discussion